[Assessment of benefits of drug therapies: memantine for Alzheimer's disease as an example].
Rüther E, Hellweg R, Janetzky W·Fortschritte der Neurologie-Psychiatrie
After the approval of a drug, which represents a first assessment, independent institutions and medical professional associations provide further evaluations. Here, the question is to be asked whether common or diverging evaluation methods exist that can have an impact on the result. In principle, two methods are used:…